<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CEVIMELINE HYDROCHLORIDE </span><br/>(cev-i-may'leen)<br/><span class="topboxtradename">Evoxac<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">cholinergic (parasympathomimetic)</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>30 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Cholinergic agent that binds to muscarinic receptors.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Increases secretion of exocrine glands, such as salivary and sweat glands. It relieves severe dry mouth.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of dry mouth in patients with Sjögren's syndrome.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to cevimeline; uncontrolled asthma; acute iritis; narrow-angle glaucoma; lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Controlled asthma; chronic bronchitis, COPD; myocardial infarction; history of nephrolithiasis or cholelithiasis; pregnancy
         (category C); older adults. Safety and effectiveness in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Dry Mouth</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 30 mg t.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give without regard to food.</li>
<li>Store refrigerated at 2°8° C (35.6°46.4° F) with occasional fluctuations between 15°30°
            C (59°86° F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span>
<span class="speceff-common">Excessive sweating, headache,</span> back pain, dizziness, fatigue, pain, hot flushes, rigors, tremor, hypertonia, myalgia, fever, eye pain, ear ache, flu-like
      symptoms. <span class="typehead">CNS:</span> Insomnia, anxiety, vertigo, depression, hyporeflexia. <span class="typehead">CV:</span> Peripheral edema, chest pain. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, diarrhea,</span> excessive salivation, dyspepsia, abdominal pain, coughing, vomiting, constipation, anorexia, dry mouth, hiccup. <span class="typehead">Respiratory:</span>
<span class="speceff-common">Rhinitis, sinusitis, upper respiratory tract infection,</span> pharyngitis, bronchitis. <span class="typehead">Skin:</span> Rash, conjunctivitis, pruritus. <span class="typehead">Special Senses:</span> Abnormal vision. <span class="typehead">Urogenital:</span> Urinary tract infection. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">beta-adrenergic agonists</span> may cause conduction disturbances; <span class="classification">parasympathomimetic drugs</span> may have additive effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed. <span class="typehead">Peak:</span> 1.52 h. <span class="typehead">Distribution:</span> Metabolism: Metabolized in liver by CYP 2D6 and 3A3/4. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of increased airway resistance, especially in patient with asthma, bronchitis, emphysema, or COPD.</li>
<li>Monitor cardiac status, especially in those with known cardiac disease or dysfunction.</li>
<li>Monitor fluid status, especially in those at risk for dehydration.</li>
<li>Lab tests: Routine blood chemistry during long-term therapy.</li>
<li>Report S&amp;S of excess cholinergic activity (e.g., diaphoresis, frequent urge to urinate, nausea and/or diarrhea).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Consult physician if confusion, dizziness, or faintness occur.</li>
<li>Report diminished night vision or depth perception.</li>
<li>Drink fluids liberally (20003000 mL/d) in the event of excessive sweating when it occurs.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>